- Home
- NCNA vs SNOA Comparison
NCNA vs SNOA Comparison
Compare NCNA & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCNA
- SNOA
- Stock Information
- Founded
- NCNA 1997
- SNOA 1999
- Country
- NCNA United Kingdom
- SNOA United States
- Employees
- NCNA N/A
- SNOA N/A
- Industry
- NCNA Biotechnology: Pharmaceutical Preparations
- SNOA Biotechnology: Pharmaceutical Preparations
- Sector
- NCNA Health Care
- SNOA Health Care
- Exchange
- NCNA Nasdaq
- SNOA Nasdaq
- Market Cap
- NCNA 6.6M
- SNOA 7.5M
- IPO Year
- NCNA 2017
- SNOA 2007
- Fundamental
- Price
- NCNA $3.86
- SNOA $4.47
- Analyst Decision
- NCNA
- SNOA
- Analyst Count
- NCNA 0
- SNOA 0
- Target Price
- NCNA N/A
- SNOA N/A
- AVG Volume (30 Days)
- NCNA 346.4K
- SNOA 178.2K
- Earning Date
- NCNA 08-20-2025
- SNOA 11-06-2025
- Dividend Yield
- NCNA N/A
- SNOA N/A
- EPS Growth
- NCNA N/A
- SNOA N/A
- EPS
- NCNA N/A
- SNOA N/A
- Revenue
- NCNA N/A
- SNOA $14,912,000.00
- Revenue This Year
- NCNA N/A
- SNOA $23.00
- Revenue Next Year
- NCNA N/A
- SNOA $24.59
- P/E Ratio
- NCNA N/A
- SNOA N/A
- Revenue Growth
- NCNA N/A
- SNOA 17.43
- 52 Week Low
- NCNA $2.78
- SNOA $1.75
- 52 Week High
- NCNA $1,650.00
- SNOA $6.92
- Technical
- Relative Strength Index (RSI)
- NCNA 41.45
- SNOA 52.23
- Support Level
- NCNA $2.82
- SNOA $4.31
- Resistance Level
- NCNA $3.60
- SNOA $4.68
- Average True Range (ATR)
- NCNA 0.24
- SNOA 0.20
- MACD
- NCNA 0.43
- SNOA -0.08
- Stochastic Oscillator
- NCNA 74.48
- SNOA 21.92
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.
About SNOA Sonoma Pharmaceuticals Inc.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.